News
09-14-2011, 01:54 AM
Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.
More... (http://www.news-medical.net/news/20110914/New-data-from-Pfizers-investigational-oncology-compounds-to-be-presented-at-EMCC-2011.aspx)
More... (http://www.news-medical.net/news/20110914/New-data-from-Pfizers-investigational-oncology-compounds-to-be-presented-at-EMCC-2011.aspx)